Select Page

How Our Algorithm Models the Drug Discovery Process

Jul 14, 2020 | Blog | 0 comments

Daniel Gigante

As I mentioned in my previous post, our CEO, Andrew Satz, recently spoke at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process. See below.

As Andrew explains, the traditional way of discovering antibodies involves injecting an animal with a disease or a virus. The animal is then going to have an immune response, producing antibodies to fight the disease. You then have an animal antibody that you now need to convert into a human antibody. This process takes roughly 4-5 years and cost over half a billion dollars.

At EVQLV, we model that entire process in the computer. In the above example, the process by which the animal is forming its immune response is evolutionary. Our algorithm models this evolutionary process in the computer, allowing us to generate millions of antibodies at a fraction of the cost and time it takes to do so in the lab. After we’ve generated our algorithms, we screen them so they’re less likely to have failure in animals or in humans. In short, we’re moving from drug discovery to computational drug design.


Submit a Comment

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...